Sera Prognostics, Inc. (NASDAQ: SERA) is a Healthcare company (Medical - Devices) with a market capitalization of $78M. The Maz Rating grades it against the other companies in its sector.
Sera Prognostics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.00, Sera Prognostics, Inc. trades at 784.1x sales and 1.9x book value. Over the last twelve months it generated about $98969 of revenue and a net loss of $27M. It runs a gross margin of -103.1%, an operating margin of -38755.2% and a net margin of -34866.7%. It shows return on equity of -52.5%, return on invested capital of -66.8% and a free cash flow yield of -37.4%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 1.88. Over the past 52 weeks the share price ranged from $1.56 to $3.85, with a beta of 1.14.
Sera Prognostics, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 4 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.